

## Technology Advisory Committee D Interests Register

**Topic: Voclosporin with immunosuppressive therapies for treating lupus nephritis [ID3962]**

**Publication Date: 03/05/2023**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Professor David Meads	Committee member	Non-financial professional	Professor Meads has conducted consultancy work for Otsuka in an unrelated area. The funding went to the University of Leeds and personally to him.	20.10.2022 & 20.01.2023	It was agreed his declaration would not prevent Professor Meads from participating in discussions on this appraisal.
Dr Matt Bradley	Committee member	Financial	Dr Bradley is employed by GSK the manufacturer of belimumab. Although this medicine hasn't been reviewed by NICE, it is licensed for use in Lupus Nephritis.	17.10.2022 & 20.01.2023	It was agreed that as a direct conflict Dr Bradley would not participate in discussions on this appraisal.
Amy Somers	Patient expert	Direct & Indirect – financial & non-financial	Amy is the Lupus Europe admin assistant (December 2019 - September 2021) and is a trustee of Lupus Europe and Lupus Europe PAN (patient advisory network) member working with pharma and academic research from	08.03.2022	It was agreed her declarations would not prevent Amy from providing expert advice to the committee

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			2018 onwards, as well as a Lupus UK northwest committee member from 2019 onwards. Amy also declared that she is on the Global Lupus patient panel for Roche, a patient advisor for Boehringer Ingelheim and a EUPATI fellow.		